Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT03630055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03630055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 3
Overall status
Terminated
Start date
October 3, 2018
Completion date
June 26, 2025
Enrollment
930 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

radial artery occlusion